Diagnóstico y tratamiento | 28 OCT 18

Enfermedad de Parkinson: revisión en profundidad

La enfermedad de Parkinson es una entidad compleja en sus manifestaciones clínicas y su tratatmiento
Autor/a: Lorraine V Kalia, Anthony E Lang The Lancet, Vol 386, issue 9996, august 29, 2015
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

1 Goetz CG. The history of Parkinson’s disease: early más tarde en el curso de la enfermedad.

 2 Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988; 51: 745–52.

3 Marras C, Lang A. Parkinson’s disease subtypes: lost in translation? J Neurol Neurosurg Psychiatry 2013; 84: 409–15.

4 Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990; 40: 1529–34.

5 Khoo TK, Yarnall AJ, Duncan GW, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 2013; 80: 276–81.

6 Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR, NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord 2011; 26: 399–406.

7 Duncan GW, Khoo TK, Yarnall AJ, et al. Health-related quality of life in early Parkinson’s disease: the impact of nonmotor symptoms. Mov Disord 2014; 29: 195–202.

8 Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord 2012; 27: 617–26.

9 American Academy of Sleep Medicine. International classifi cation of sleep disorders: diagnostic and coding manual, 2nd edn. Westchester, IL: American Academy of Sleep Medicine, 2005.

 10 Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 2010; 6: 85–95.

11 Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009; 72: 1296–300.

 12 Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med 2013; 14: 744–48.

 13 Iranzo A, Tolosa E, Gelpi E, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol 2013; 12: 443–53.

14 Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 2012; 72: 893–901.

15 Siderowf A, Lang AE. Premotor Parkinson’s disease: concepts and defi nitions. Mov Disord 2012; 27: 608–16.

16 Hely MA, Morris JGL, Reid WGJ, Traffi cante R. Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005; 20: 190–99.

17 Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837–44

18 Coelho M, Ferreira JJ. Late-stage Parkinson disease. Nat Rev Neurol 2012; 8: 435–42.

19 Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007; 68: 384–86.

20 Alzheimer’s Association. 2014 Alzheimer’s disease facts and fi gures. Alzheimers Dement 2014; 10: e47–e92.

 21 Von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 2005; 15: 473–90.

22 Strickland D, Bertoni JM. Parkinson’s prevalence estimated by a state registry. Mov Disord 2004; 19: 318–23.

 23 Bauso DJ, Tartari JP, Stefani CV, Rojas JI, Giunta DH, Cristiano E. Incidence and prevalence of Parkinson’s disease in Buenos Aires City, Argentina. Eur J Neurol 2012; 19: 1108–13.

24 Okubadejo NU, Bower JH, Rocca WA, Maraganore DM. Parkinson’s disease in Africa: a systematic review of epidemiologic and genetic studies. Mov Disord 2006; 21: 2150–56.

25 Muangpaisan W, Hori H, Brayne C. Systematic review of the prevalence and incidence of Parkinson’s disease in Asia. J Epidemiol 2009; 19: 281–93.

26 Benamer HTS, de Silva R, Siddiqui KA, Grosset DG. Parkinson’s disease in Arabs: a systematic review. Mov Disord 2008; 23: 1205–10.

 27 Van Den Eeden SK. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157: 1015–22.

28 De Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol 2006; 5: 525–35

. 29 Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 2009; 72: 432–38.

30 Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2014; 29: 1583–90.

 31 Ritz B, Lee PC, Lassen CF, Arah OA. Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. Neurology 2014; 83: 1396–402.

 32 Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson’s disease risk, diagnosis and prognosis. Biomark Med 2010; 4: 701–12.

 33 Mortimer JA, Borenstein AR, Nelson LM. Associations of welding and manganese exposure with Parkinson disease: review and meta-analysis. Neurology 2012; 79: 1174–80.

 34 Foubert-Samier A, Helmer C, Perez F, et al. Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. Neurology 2012; 79: 1615–21.

35 Goldman SM, Quinlan PJ, Ross GW, et al. Solvent exposures and Parkinson disease risk in twins. Ann Neurol 2012; 71: 776–84.

36 Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identifi ed in families with Parkinson’s disease. Science 1997; 276: 2045–47.

37 Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson’s disease. Physiol Rev 2011; 91: 1161–218.

 38 Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol 2012; 11: 986–98.

39 Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 2009; 361: 1651–61.

40 Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifi es six new risk loci for Parkinson’s disease. Nat Genet 2014; 46: 989–93.

41 Lee P-C, Bordelon Y, Bronstein J, Ritz B. Traumatic brain injury, paraquat exposure, and their relationship to Parkinson disease. Neurology 2012; 79: 2061–66.

42 Popat RA, Van Den Eeden SK, Tanner CM, et al. Coff ee, ADORA2A, and CYP1A2: the caff eine connection in Parkinson’s disease. Eur J Neurol 2011; 18: 756–65.

43 Hamza TH, Chen H, Hill-Burns EM, et al. Genome-wide gene-environment study identifi es glutamate receptor gene GRIN2A as a Parkinson’s disease modifi er gene via interaction with coff ee. Plos Genet 2011; 7: e1002237.

 44 Goldman SM, Kamel F, Ross GW, et al. Head injury, alpha-synuclein Rep1, and Parkinson’s disease. Ann Neurol 2012; 71: 40–48.

 45 Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson’s disease: refi ning the diagnostic criteria. Lancet Neurol 2009; 8: 1150–57.

 46 Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 2013; 136: 2419–31.

47 Dickson DW. Parkinson’s disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med 2012; 2: a009258.

 48 Masters CL, Kril JJ, Halliday GM, et al. Overview and recent advances in neuropathology. Part 2: Neurodegeneration. Pathology 2011; 43: 93–102.

49 Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839–40.

 50 Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol 2012; 9: 13–24.

51 Iwanaga K, Wakabayashi K, Yoshimoto M, et al. Lewy body-type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases. Neurology 1999;

 52: 1269–71. 52 Fumimura Y, Ikemura M, Saito Y, et al. Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in lewy body disease. J Neuropathol Exp Neurol 2007; 66: 354–62.

 53 Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010; 119: 689–702.

54 Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathol 2010; 119: 703–13.

55 Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 197–211.

 56 Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinson’s disease. Brain 2009; 132: 2947–57.

57 Kempster PA, O’Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study. Brain 2010; 133: 1755–62.

58 Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012; 72: 587–98.

59 Parkkinen L, Pirttilä T, Alafuzoff I. Applicability of current staging/ categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 2008; 115: 399–407.

60 Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol 2008; 115: 409–15. 61 Saito Y, Kawashima A, Ruberu NN, et al. Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 2003; 62: 644–54.

 62 Kovacs GG, Wagner U, Dumont B, et al. An antibody with high reactivity for disease-associated α-synuclein reveals extensive brain pathology. Acta Neuropathol 2012; 124: 37–50.

63 Schulz-Schaeff er WJ. The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol 2010; 120: 131–43.

 64 Cremades N, Cohen SIA, Deas E, et al. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 2012; 149: 1048–59.

 65 Kalia LV, Kalia SK, McLean PJ, Lozano AM, Lang AE. α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol 2013; 73: 155–69.

 66 Compta Y, Parkkinen L, O’Sullivan SS, et al. Lewy- and Alzheimertype pathologies in Parkinson’s disease dementia: which is more important? Brain 2011; 134: 1493–505.

67 Irwin DJ, Lee VM-Y, Trojanowski JQ. Parkinson’s disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci 2013; 14: 626–36.

68 Doherty KM, Silveira-Moriyama L, Parkkinen L, et al. Parkin disease: a clinicopathologic entity? JAMA Neurol 2013; 70: 571–79.

 69 Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson’s disease. Mov Disord 2012; 27: 831–42.

70 Kalia LV, Lang AE, Hazrati LN, et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson’s disease. JAMA Neurol 2015; 72: 100–05.

71 Tansey MG, Goldberg MS. Neuroinfl ammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010; 37: 510–18.

72 Phani S, Loike JD, Przedborski S. Neurodegeneration and infl ammation in Parkinson’s disease. Parkinsonism Relat Disord 2012; 18: S207–09.

73 Devine MJ, Gwinn K, Singleton A, Hardy J. Parkinson’s disease and alpha-synuclein expression. Mov Disord 2011; 26: 2160–68.

74 Cookson MR. Cellular eff ects of LRRK2 mutations. Biochem Soc Trans 2012; 40: 1070–73.

75 Dzamko N, Halliday GM. An emerging role for LRRK2 in the immune system. Biochem Soc Trans 2012; 40: 1134–39.

76 Lee S, Imai Y, Gehrke S, Liu S, Lu B. The synaptic function of LRRK2. Biochem Soc Trans 2012; 40: 1047–51.

77 Sanna G, Del Giudice MG, Crosio C, Iaccarino C. LRRK2 and vesicle traffi cking. Biochem Soc Trans 2012; 40: 1117–22.

78 Martin I, Kim JW, Lee BD, et al. Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson’s disease. Cell 2014; 157: 472–85.

79 Paisán-Ruíz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 2004; 44: 595–600.

 80 Healy DG, Falchi M, O’Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol 2008; 7: 583–90.

81 Aasly JO, Vilariño-Güell C, Dachsel JC, et al. Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson’s disease. Mov Disord 2010; 25: 2156–63.

82 Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews. N Engl J Med 2006; 354: 424–25.

83 Lesage S, Dürr A, Tazir M, et al. LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. N Engl J Med 2006; 354: 422–23.

 84 Zimprich A, Benet-Pagès A, Struhal W, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 2011; 89: 168–75.

85 Vilariño-Güell C, Wider C, Ross OA, et al. VPS35 mutations in Parkinson disease. Am J Hum Genet 2011; 89: 162–67.

86 Chartier-Harlin M-C, Dachsel JC, Vilariño-Güell C, et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet 2011; 89: 398–406.

87 Vilariño-Güell C, Rajput A, Milnerwood AJ, et al. DNAJC13 mutations in Parkinson disease. Hum Mol Genet 2014; 23: 1794–801.

 88 Funayama M, Ohe K, Amo T, et al. CHCHD2 mutations in autosomal dominant late-onset Parkinson’s disease: a genome-wide linkage and sequencing study. Lancet Neurol 2015; 14: 274–82.

 89 Bonifacino JS, Hurley JH. Retromer. Curr Opin Cell Biol 2008; 20: 427–36.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024